Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | TRPM4 | Q8TD43 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.57 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13744249 | 0.82 | NOTUM (0.74) | SMN1; SMN2GAAMAPK1NOTUMKMT2A | |
| SCHEMBL8689307 | 0.81 | HCAR2 (0.72) | SMN1; SMN2GAATRPM4HCAR2KMT2A | |
| SCHEMBL5150684 | 0.80 | MEN1 (0.72) | SMN1; SMN2TRPM4MAPK1NOTUMHCAR2 | |
| SCHEMBL4912967 | 0.80 | TRPM4 (0.77) | SMN1; SMN2GAATRPM4HCAR2KMT2A | |
| SCHEMBL8689335 | 0.80 | HSD17B10 (0.77) | SMN1; SMN2GAAHCAR2KMT2AMEN1 | |
| SCHEMBL8689129 | 0.80 | HCAR2 (0.60) | SMN1; SMN2TRPM4NOTUMHCAR2KMT2A | |
| SCHEMBL4913355 | 0.80 | L3MBTL1 (0.64) | SMN1; SMN2TRPM4HCAR2KMT2AMEN1 | |
| SCHEMBL26334075 | 0.79 | SMN1; SMN2 (0.69) | SMN1; SMN2GAAMAPK1NOTUMKMT2A | |
| SCHEMBL5696401 | 0.79 | KDM4E (0.64) | SMN1; SMN2TRPM4MAPK1HCAR2KMT2A | |
| SCHEMBL6032429 | 0.78 | HCAR2 (0.81) | SMN1; SMN2HCAR2KMT2AMEN1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269333-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2008-10-30 | — | — | US | claimed |
| US-7408078-B2 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | WYETH (US) | 2008-08-05 | — | — | US | claimed |
| US-20050004192-A1 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | VIROPHARMA INCORPORATED | 2005-01-06 | — | — | US | claimed |
| US-20080269333-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
| US-7408078-B2 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | WYETH (US) | 2008-08-05 | — | — | US | disclosed |
| US-20050004192-A1 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | VIROPHARMA INCORPORATED | 2005-01-06 | — | — | US | disclosed |
| WO-2004091724-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2004-10-28 | — | — | WO | disclosed |
| US-5741926-A | ANTIDIABETIC AGENT | SHAMAN PHARMACEUTICALS, INC. (US) | 1998-04-21 | — | — | US | disclosed |
| WO-1997030019-A1 | ANILINE DERIVATIVES HAVING ANTIHYPERGLYCEMIC ACTIVITY | SHAMAN PHARMACEUTICALS, INC. (US) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004192-A1 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | HCCS, ALAD, HAVCR2 | SMN1; SMN2 4765/4885GAA 212/4885TRPM4 4134/4885 |
| US-20080269333-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | HCCS, ALAD, HAVCR2 | SMN1; SMN2 4765/4885GAA 212/4885TRPM4 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.